Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19

Ryan M Close; T Shaifer Jones; Christopher Jentoft; James B McAuley

doi:10.1001/jamanetworkopen.2021.25866

Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19

JAMA Netw Open. 2021 Sep 1;4(9):e2125866. doi: 10.1001/jamanetworkopen.2021.25866.

Authors

Ryan M Close¹, T Shaifer Jones¹, Christopher Jentoft¹, James B McAuley¹

Affiliation

¹ Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona.

Abstract

This quality improvement study compares outcomes among high-risk Native American patients who did or did not receive monoclonal antibody treatment for COVID-19.

Publication types

Comparative Study

MeSH terms

Adolescent
Adult
American Indian or Alaska Native*
Antibodies, Monoclonal, Humanized / therapeutic use*
Arizona / epidemiology
COVID-19 / mortality
COVID-19 Drug Treatment*
Female
Hospital Mortality*
Hospitalization* / statistics & numerical data
Humans
Male
Middle Aged
Pandemics
Retrospective Studies
Rural Population
SARS-CoV-2
Severity of Illness Index
Treatment Outcome
Young Adult

Substances

Antibodies, Monoclonal, Humanized
imdevimab
bamlanivimab
casirivimab